{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:20:07Z","timestamp":1758702007004},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>In insulin-like growth factor II (IGF-II) producing non-islet cell tumor hypoglycemia (NICTH), high molecular weight forms of IGF-II (big IGF-II) are produced as a cause of spontaneous hypoglycemia. MicroRNA (miRNA)-483 family, encoded in an intron lesion of <jats:italic>IGF2<\/jats:italic> gene, is suggested to be co-expressed with IGF-II. Here, we tested whether serum miR-483-5p and -3p levels are associated with the presence of big IGF-II in NICTH.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design<\/jats:title>\n<jats:p>Serum samples from patients who were suspected to have IGF-II producing NICTH (<jats:italic>n<\/jats:italic> = 42) were tested. MiR-483-5p and -3p levels were evaluated using quantitative PCR. IGF-II level was analyzed using ELISA. The presence of big IGF-II was identified by Western blotting.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Big IGF-II was detected in the sera of 32 patients. MiR-483-5p (<jats:italic>P<\/jats:italic> = 0.0015) and -3p (<jats:italic>P<\/jats:italic> = 0.027) levels were significantly higher in sera with big IGF-II (<jats:italic>n<\/jats:italic> = 32) than in those without (<jats:italic>n<\/jats:italic> = 10), whereas serum IGF-II level (<jats:italic>P<\/jats:italic> = 0.055) was not significantly different between the groups. The median serum concentration of miR-483-5p was ~10 times higher than that of miR-483-3p. Although a strong correlation was observed between the two miRNAs (<jats:italic>r<\/jats:italic> = 0.844, <jats:italic>P<\/jats:italic> &lt; 0.0001), but neither of which was correlated with serum IGF-II level. The areas under the receiver operating characteristic curves of miR-483-5p (0.853) and -3p (0.722) were higher than that of IGF-II (0.694) for detecting the presence of big IGF-II.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The associations of serum miR-483-5p and -3p levels with the presence of big IGF-II suggest the diagnostic potential of these miRNAs for IGF-II producing NICTH.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-20-0706","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T15:37:21Z","timestamp":1603899441000},"page":"41-49","update-policy":"http:\/\/dx.doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic potential of miR-483 family for IGF-II producing non-islet cell tumor hypoglycemia"],"prefix":"10.1093","volume":"184","author":[{"given":"Mototsugu","family":"Nagao","sequence":"first","affiliation":[{"name":"1Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan"},{"name":"2Islet Cell Exocytosis, Department of Clinical Sciences Malm\u00f6, Lund University, Malm\u00f6, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Asai","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L S","family":"Esguerra","sequence":"additional","affiliation":[{"name":"2Islet Cell Exocytosis, Department of Clinical Sciences Malm\u00f6, Lund University, Malm\u00f6, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Hizuka","sequence":"additional","affiliation":[{"name":"3Tokyo Women\u2019s Medical University, Sinjuku-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Eliasson","sequence":"additional","affiliation":[{"name":"2Islet Cell Exocytosis, Department of Clinical Sciences Malm\u00f6, Lund University, Malm\u00f6, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sugihara","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/184\/1\/EJE-20-0706.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/184\/1\/EJE-20-0706.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:15:24Z","timestamp":1676391324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/184\/1\/41\/6653825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje-20-0706","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}